title: Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up.
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Helbig
authors.forename: Andrzej
authors.initials: A
authors.lastname: Moskwa
authors.forename: Alina
authors.initials: A
authors.lastname: Swiderska
authors.forename: Alina
authors.initials: A
authors.lastname: Urbanowicz
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Całbecka
authors.forename: Justyna
authors.initials: J
authors.lastname: Gajkowska
authors.forename: Barbara
authors.initials: B
authors.lastname: Zdziarska
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Brzeźniakiewicz
authors.forename: Joanna
authors.initials: J
authors.lastname: Pogrzeba
authors.forename: Sławomira
authors.initials: S
authors.lastname: Krzemień
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000235:genetics; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha; D055815:Young Adult; D039221:mRNA Cleavage and Polyadenylation Factors
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha